Ensign Peak Advisors, Inc Lyra Therapeutics, Inc. Transaction History

Ensign Peak Advisors, Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$4.55 - $6.53 $1.32 Million - $1.89 Million	289,778 Added 96.1%	591,311 $3.68 Million
Q3 2023 Nov 13, 2023	SELL	$2.95 - $4.8 $2,070 - $3,369	-702 Reduced 0.23%	301,533 $1.18 Million
Q4 2022 Feb 13, 2023	BUY	$2.44 - $5.42 $583,221 - $1.3 Million	239,025 Added 378.14%	302,235 $949,000
Q3 2022 Nov 14, 2022	BUY	$4.95 - $6.6 $34,555 - $46,074	6,981 Added 12.42%	63,210 $317,000
Q2 2022 Aug 12, 2022	BUY	$4.12 - $7.51 $70,295 - $128,135	17,062 Added 43.56%	56,229 $318,000
Q3 2020 Nov 12, 2020	BUY	$10.61 - $13.96 $256,411 - $337,371	24,167 Added 161.11%	39,167 $438,000
Q2 2020 Aug 12, 2020	BUY	$10.91 - $18.56 $163,650 - $278,400	15,000 New	15,000 $170,000

32.2M

21.1K

400

Ticker LYRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,826,400
Market Cap $5.73M
Description
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.